血浆蛋白质组学证据提示SARS-CoV-2感染后β-淀粉样蛋白病理增加
研究基于英国生物样本库,在血清学确诊SARS-CoV-2感染前后测量与阿尔茨海默病病理相关的血浆生物标志物。感染与β-淀粉样蛋白病理相关标志物改变有关:血浆Aβ42:Aβ40比值降低,在更脆弱参与者中血浆Aβ42降低、pTau-181升高。上述标志物改变在因COVID-19住院或既往报告高血压的参与者中更大,并与阿尔茨海默病相关脑结构影像模式、较低认知测试评分和较差整体健康评估相关。
要点
- SARS-CoV-2感染与血浆Aβ42:Aβ40比值降低相关。
- 更脆弱参与者感染后血浆Aβ42降低、pTau-181升高。
- 因COVID-19住院或既往高血压者血浆标志物改变更大。
核心结论
- 这项事后病例对照匹配研究提供观察性生物标志物证据,提示SARS-CoV-2感染可能与老年人更严重的脑β-淀粉样蛋白病理相关。
- 结果不能确立因果关系,但提示SARS-CoV-2(可能还有其他系统性炎症疾病)可能增加未来阿尔茨海默病风险。
研究设计与样本
- 事后病例对照匹配研究,基于英国生物样本库,在血清学确诊SARS-CoV-2感染前后测量与阿尔茨海默病病理相关的血浆生物标志物。
主要发现
- SARS-CoV-2感染与β-淀粉样蛋白病理相关标志物改变有关:血浆Aβ42:Aβ40比值降低,在更脆弱参与者中血浆Aβ42降低、血浆pTau-181升高。
- 因COVID-19住院的参与者及既往报告高血压的参与者,血浆生物标志物改变更大。
- 血浆生物标志物改变与阿尔茨海默病相关脑结构影像模式、较低认知测试评分和较差整体健康评估相关。
局限性
- 原文指出这些结果不能确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Previous studies have suggested that systemic viral infections may increase risks of dementia. Whether this holds true for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infections is unknown. Determining this is important for anticipating the potential future incidence of dementia. To begin to do this, we measured plasma biomarkers linked to Alzheimer's disease pathology in the UK Biobank before and after serology-confirmed SARS-CoV-2 infections. SARS-CoV-2 infection was associated with biomarkers associated with β-amyloid pathology: reduced plasma Aβ42:Aβ40 ratio and, in more vulnerable participants, lower plasma Aβ42 and higher plasma pTau-181. The plasma biomarker changes were greater in participants who had been hospitalized with COVID-19 or had reported hypertension previously. We showed that the changes in biomarkers were linked to brain structural imaging patterns associated with Alzheimer's disease, lower cognitive test scores and poorer overall health evaluations. Our data from this post hoc case-control matched study thus provide observational biomarker evidence that SARS-CoV-2 infection can be associated with greater brain β-amyloid pathology in older adults. While these results do not establish causality, they suggest that SARS-CoV-2 (and possibly other systemic inflammatory diseases) may increase the risk of future Alzheimer's disease.
引用
- Duff EP, Zetterberg H, Heslegrave A, et al. Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection. Nat Med. 2025. PMID: 39885359. doi:10.1038/s41591-024-03426-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。